Waksal Harlan has filed 4 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 128333 shares of Lyra Therapeutics, Inc. ($LYRA) on December 09, 2024.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 9, 2024 | Lyra Therapeutics, Inc. | $LYRA | Waksal Harlan | Executive Chair | A | Performance-based Restricted Stock Units | 128333 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 18, 2024 | Lyra Therapeutics, Inc. | $LYRA | Waksal Harlan | Executive Chair | A | Common Stock | 275000 | $0.00 | 536,966.0000 | 0 | 104.98% | 0.00% |
| Nov. 10, 2023 | Lyra Therapeutics, Inc. | $LYRA | Waksal Harlan | Executive Chair | P | Common Stock | 25000 | $2.96 | 261,966.0000 | 0 | 10.55% | 0.00% |
| Jan. 31, 2023 | Lyra Therapeutics, Inc. | $LYRA | Waksal Harlan | Executive Chair | A | Stock Option | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |